Moderate Sustained Virologic Response Rates with 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients with Advanced Liver Disease

Clinical Infectious Diseases

Volumn 62, Issue 4, 2015, Pages 440-447

  Kattakuzhy, Sarah ^a   Wilson, Eleanor ^a   Sidharthan, Sreetha ^b   Sims, Zayani ^b   McLaughlin, Mary ^c   Price, Angie ^a   Silk, Rachel ^a   Gross, Chloe ^a   Akoth, Elizabeth ^a   McManus, Maryellen ^e   Emmanuel, Benjamin ^a   Shrivastava, Shikha ^a   Tang, Lydia ^a   Nelson, Amy ^a   Teferi, Gebeyehu ^f   Chavez, Jose ^f   Lam, Brian ^g   Mo, Hongmei ^h   Osinusi, Anuoluwapo ^h   Polis, Michael A ^d   Masur, Henry ^b   Kohli, Anita ⁱ   Kottilil, Shyamasundaran ^a   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Laboratory of Immunoregulation   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e ParkerTide   (United States)

^f Unity Health Care   (United States)

^g INOVA FAIRFAX HOSPITAL   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ CREIGHTON UNIVERSITY   (United States)

Author keywords

advanced fibrosis; hepatitis C; short duration

Indexed keywords

ALANINE AMINOTRANSFERASE; LEDIPASVIR PLUS SOFOSBUVIR; VEDROPREVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; GS-9451; LEDIPASVIR; QUINOLINE DERIVATIVE; SOFOSBUVIR;

ADULT; ANGINA PECTORIS; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COLITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER FIBROSIS; MALE; MIDDLE AGED; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AGED; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; PATHOLOGY; PROCEDURES; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUINOLINES; SOFOSBUVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959922676     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ897     Document Type: Article

References (22)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347:975-82.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med 2011; 364:2405-16.
4. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
5. Limaye AR, Draganov PV, Cabrera R. Boceprevir for chronic HCV genotype 1 infection. New Engl J Med 2011; 365:176-8.
6. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11.
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med 2014; 370:1483-93.
8. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med 2014; 370:1889-98.
9. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New Engl J Med 2014; 370:1983-92.
10. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J Med 2014; 370:1973-82.
11. McCarthy M. New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US. Brit Med J 2015; 350:h2055.
12. Peterson T, Gordon LA, Townsend K, et al. Pill burden and treatment length reduce adherence to IFN-free hepatitis C therapy in an urban cohort [abstract 667]. In: 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014.
13. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J Med 2014; 370:1879-88.
14. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015; 385:1107-13.
15. http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/ daidsaegradingtable.pdf.
16. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7:1617-31.
17. Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015; 35:1923-33.
18. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313:1736-44.
19. Guedj H, Guedj J, Negro F, et al. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepatitis 2012; 19:488-96.
20. Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209:1700-4.
21. Perelson AS, Guedj J. Modelling hepatitis C therapy-predicting effects of treatment. Nat Rev Gastroenterol Hepatol. 2015; 12:437-45.
22. Kohli A, Kattakuzhy S, Kottilil S, et al. Four-week directly acting anti-HCV regimens in HCV genotype-1 patients without cirrhosis. Ann Intern Med 2015, publication pending.